The American College of Radiology lauded the AMA’s policy update that recognizes the importance of screening mammography starting at age 40.
The American College of Radiology lauded the American Medical Association’s policy update this week that recognizes the importance of breast cancer screening mammography starting at age 40.
Paul Ellenbogen, MD, FACR, chair of the ACR Board of Chancellors, noted that since mammography screening became widespread, the breast cancer death rate in the U.S. had dropped more than 30 percent - even among women ages 40 to 49.
“The ACR urges women ages 40-and-over to receive annual mammograms,” he said in a statement. “Women need access to these lifesaving exams. Government and insurers should not get in the way of this care.”
The ACR noted its support of several items in the AMA’s position, including that the AMA:
• recognizes the mortality reduction benefit of screening mammography and supports its use as a tool to detect breast cancer.
• believes that beginning at the age of 40 years, all women should be eligible for screening mammography.
The AMA also supports insurance coverage for screening mammography, and encourages physicians to discuss the benefits and risks with their patients.
The ACR also praised the AMA’s resolution expressing concern about the recent recommendations by the United States Preventative Service Task Force that would limit screening to women over 50. The AMA also encouraged the USPSTF to “implement procedures that allow for meaningful input on recommendation development from specialists and stakeholders in the topic area under study.”
“The bottom line is that discontinuing regular mammograms may save a few dollars in the short term, but will result in thousands more breast cancer deaths each year,” Barbara Monsees, MD, chair of the ACR Breast Imaging Commission, said in a statement. “That human cost is too high.”
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.